De Novo classification is an FDA pathway that lets a novel medical device of low to moderate risk reach the U.S. market without a predicate. Submitted under section 513(f)(2) of the FD&C Act, it requests classification into Class I or Class II and, when granted, creates a new device type.
What is De Novo classification?
De Novo classification (formally, evaluation of automatic Class III designation) is the route a manufacturer takes when a device has no legally marketed predicate but does not warrant the scrutiny of premarket approval. By default, any device without a predicate is automatically designated Class III, the highest risk tier. The De Novo request asks the FDA to look at the actual risk profile and reclassify the device into Class I or Class II instead.
A granted request does two things at once. It authorizes the specific device for marketing, and it establishes a new classification regulation, with the general controls, or general and special controls, that later devices of the same type can rely on. A successful De Novo becomes a predicate for future 510(k) submissions.
Why De Novo classification matters in medical device development
For a genuinely new device, the pathway you pick shapes budget, timeline, and evidence burden. Forcing a low-risk product down the Class III Premarket Approval (PMA) route means clinical trials and costs that the risk does not justify. De Novo classification offers a proportionate middle path: more rigorous than a plain 510(k), far lighter than PMA.
Getting it wrong is expensive. Submit a 510(k) with no valid predicate, and the FDA returns a Not Substantially Equivalent (NSE) letter, resetting your clock. Draft weak special controls, and you can saddle every follow-on device, including your own next model, with mitigations that do not fit. The classification you win also shapes your competitive position, since it sets the bar that later entrants must clear.
How De Novo classification works
A De Novo request can reach the FDA in two ways. A direct De Novo goes in without a preceding submission. A post-NSE De Novo follows a 510(k) that the FDA found Not Substantially Equivalent. The 21st Century Cures Act removed the old 30-day deadline for the post-NSE route, so timing is more flexible now.
The core steps:
- Confirm eligibility. Verify there is no predicate and that general controls, or general and special controls, can give reasonable assurance of safety and effectiveness. Class III risk profiles do not qualify.
- Engage FDA early. An FDA Pre-Submission (Q-Sub) meeting helps align on testing and proposed special controls before you build the full data package.
- Build the technical sections. Generate nonclinical bench data, biocompatibility, electrical safety, EMC, software, and clinical evidence where needed, following the content requirements in 21 CFR 860.220.
- Submit through eSTAR. As of October 1, 2025, De Novo requests must use the eSTAR template and be submitted through the CDRH Customer Collaboration Portal, unless exempted.
- Acceptance and substantive review. FDA performs an acceptance review under 21 CFR 860.230, followed by a substantive scientific review that ends with either a grant or a decline order.
The process is codified in 21 CFR Part 860, Subpart D, which took effect in January 2022. The evidence still relies on familiar standards, including:
- ISO 14971 for risk management
- FDA QMSR (aligned with ISO 13485) for quality system requirements
- IEC 60601-1 for electrical safety
- IEC 62304 for medical device software lifecycle processes
For AI or machine-learning devices, a Predetermined Change Control Plan (PCCP) can be included within the request to pre-authorize defined algorithm updates.
Common challenges and best practices
The most common failure is a weak intended-use statement. Because a De Novo creates a brand-new device type, the wording of the indication and the special controls becomes the template FDA applies to everyone who follows. Vague or overbroad language invites reviewer pushback and can produce controls you cannot meet.
Teams also underestimate assembly time. Even with Pre-Sub feedback in hand, pulling together the technical sections, drafting proposed special controls, and writing a coherent benefit-risk rationale often takes months.
Successful programs typically:
- Develop the risk management file early.
- Build test protocols before verification begins.
- Maintain traceability from design controls to every claim and supporting evidence.
- Treat proposed special controls as a design input rather than a final regulatory document.
- Budget for the applicable MDUFA user fee, while noting that pediatric-only requests are exempt and qualified small businesses may receive a reduced fee.
How SJML helps with De Novo classification
Syrma Johari MedTech supports De Novo programs as part of its Compliance-as-a-Service offering, pairing regulatory strategy with the engineering and testing a request depends on. SJML’s QARA team advises on device classification and FDA submission strategy, prepares technical files and design history documentation, and structures risk management to ISO 14971. In-house labs run the electrical safety, EMC, and reliability testing that feed the nonclinical sections, while design and quality teams keep design controls traceable from claim to evidence. Startups and established OEMs both use this end-to-end support to plan a defensible route to market.
Frequently asked questions
A 510(k) demonstrates that a device is substantially equivalent to a legally marketed predicate. De Novo classification applies when no predicate exists. Instead of proving equivalence, the manufacturer provides risk and performance evidence so the FDA can classify the novel device into Class I or Class II. A granted De Novo can then serve as the predicate for later 510(k) submissions.
FDA’s MDUFA V performance goals target a decision within roughly 150 FDA review days, but real timelines usually run longer because of acceptance review, interactive review, and requests for additional information. Preparing the submission itself often takes several months. Early Pre-Submission engagement and a complete, well-organized package are the most reliable ways to reduce delays.
Not always. Many De Novo requests are supported primarily by nonclinical bench testing, biocompatibility, and other laboratory evidence. Clinical evidence is generally required only when bench testing cannot adequately address the device’s key risks. FDA’s expectations scale with the device’s risk profile, intended use, and remaining residual risks.
Yes. When the FDA grants a De Novo request, it creates a new classification regulation and establishes a new device type. Future devices of the same type can use the granted device as a predicate through the 510(k) pathway, provided they satisfy the established special controls. This is why the wording of the original intended use and special controls is so important.
Related terms
- 510(k) Premarket Notification
- Predicate Device
- Premarket Approval (PMA)
- Special Controls
- FDA Device Classification
